THE WOODLANDS, Texas, Jan. 26 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. will hold a conference call on Thursday, January 28, 2010 at 11:30 am Eastern Time to discuss its recent top-line Phase 2 clinical results with LX4211, Lexicon's once-per-day, orally-delivered, small molecule drug candidate for the treatment of type 2 diabetes mellitus.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for diabetes, autoimmune disease, carcinoid syndrome, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
CONTACT: D. Wade Walke, Ph.D., Director, Corporate Communications of
Lexicon Pharmaceuticals, Inc., +1-281-863-3046, wwalke@lexpharma.com
Web site: http://www.lexpharma.com/
